HAEMONETICS CORP

Form 4

February 10, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL OMB 3235-0287

Number:

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

subject to Section 16. Form 4 or Form 5 obligations may continue.

Check this box

if no longer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Addre White Jonathan	•	g Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer		
			HAEMONETICS CORP [HAE]	(Check all applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction			
400 WOOD ROAD			(Month/Day/Year) 02/07/2014	Director 10% Owner _X_ Officer (give title Other (specify below) Chief Science and Technology		
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
BRAINTREE, MA 02184			Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Citv)	(State)	(Zip)	Table I Non Darker Committee Ann			

(City)	(State)	Table	e I - Non-D	erivative	Secur	rities Acqui	ired, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			d of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
G			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(III3II. 4)	
Common Stock	02/07/2014		S	700	D	\$ 38.66	26,346	D	
Common Stock	02/07/2014		S	315	D	\$ 38.672	26,031	D	
Common Stock	02/07/2014		S	865	D	\$ 38.66	25,166	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

Edgar Filing: HAEMONETICS CORP - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		·	7. Title and A Underlying S (Instr. 3 and	Secur
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Am or Num of S
Non-Qualified Stock Option (right to buy)	\$ 26.47					10/27/2010(1)	10/27/2016	Common Stock	24
Non-Qualified Stock Option (right to buy)	\$ 27.495					10/27/2011(1)	10/27/2017	Common Stock	30
Non-Qualified Stock Option (right to buy)	\$ 30.025					01/28/2010(1)	01/28/2016	Common Stock	35
Non-Qualified Stock Option (right to buy)	\$ 30.67					10/25/2012(1)	10/25/2018	Common Stock	35
Non-Qualified Stock Option (right to buy)	\$ 33.925					07/20/2012(1)	07/20/2018	Common Stock	27
Non-Qualified Stock Option (right to buy)	\$ 39.055					10/24/2013(1)	10/24/2019	Common Stock	32
Non-Qualified Stock Option (right to buy)	\$ 41.66					10/23/2014(1)	10/23/2019	Common Stock	28
Performance Shares	\$ 0					03/31/2017(2)	12/31/2017(2)	Common Stock	25

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		

Reporting Owners 2

White Jonathan 400 WOOD ROAD BRAINTREE, MA 02184

Chief Science and Technology

Signatures

By: Alexander Steffan For: Jonathan White

02/10/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and

therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3